Valeant Pharma (VRX), Other Pharma Stocks Weaker as Clinton Op-Ed Discusses Measures on Drug Prices

Valeant Pharma (NYSE: VRX), Mallinckrodt (NYSE: MNK), Horizon Pharma (NASDAQ: HZNP), Mylan (NYSE: MYL) and other pharma stocks are weaker possibly as investors read into Hillary Clinton's comments in a NEJM op-ed overnight.

According to Evecore ISI's Umer Raffat, they key paragraph that all biopharma folks would care about:

Second, to directly address rising prescription drug costs, I will work to remove barriers to competition by streamlining approval of high-quality biosimilar and generic drugs. That includes proposals to ensure that drug companies justify their prices, eliminate "pay to delay" practices, and allow Medicare to directly negotiate for better prices. I will also create a new Federal consumer response team charged with identifying excessive price spikes in long-standing, life-saving treatments, and give them effective new tools to respond.

VRX is down 3.9%, MNK is down 3.8%, HZNP is down 2.9% and MYL is down 4.7%.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Boeing (BA) Cut To Baa3 From Baa2 By Moody's, Outlook Negative
• Deutsche Bank Upgrades Acadia Healthcare (ACHC) to Hold 'on a neutral risk/ reward'